[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367032-105":59,"doc-detail-367032-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","optical-molecular-imaging-in-oral-and-oropharyngeal-squamous-cell-carcinoma-using-a-novel-upar-targeting-near-infrared-imaging-agent-fg001-an-explorative-phase-ii-clinical-trial","Optical molecular imaging in oral-and oropharyngeal squamous cell carcinoma using a novel uPAR-targeting near-infrared imaging agent FG001 - An explorative phase II clinical trial","","Frequent inadequate surgical margins in oral and oropharyngeal squamous cell carcinoma require precise intraoperative identification and delineation of malignant tissue to improve outcomes. This prospective, open-label, single-center, single-dose exploratory phase II trial evaluated the uPAR-targeting near-infrared agent FG001 for real-time detection. Macroscopic performance was quantified using sensitivity and tumor-to-background ratio, while microscopic specificity was assessed via co-localization of tumor tissue, uPAR expression, and optical signals. Safety monitoring included pharmacokinetic sampling up to 44 hours post-injection.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/optical-molecular-imaging-in-oral-and-oropharyngeal-squamous-cell-carcinoma-using-a-novel-upar-targeting-near-infrared-imaging-agent-fg001-an-explorative-phase-ii-clinical-trial/367032/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/optical-molecular-imaging-in-oral-and-oropharyngeal-squamous-cell-carcinoma-using-a-novel-upar-targeting-near-infrared-imaging-agent-fg001-an-explorative-phase-ii-clinical-trial/367032.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does the trial address in OSCC and OPSCC surgery?","Question",{"text":112,"@type":113},"In oral and oropharyngeal squamous cell carcinoma, inadequate surgical margins can leave viable tumor cells, driving recurrence risk and worsening survival outcomes. The study targets the need for more precise intraoperative identification and delineation of cancerous tissue.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was FG001 evaluated during the exploratory phase II trial?",{"text":117,"@type":113},"The trial assessed intraoperative real-time optical detection using sensitivity and tumor-to-background ratio (TBR). Microscopic specificity was evaluated by co-localization analysis between tumor tissue, uPAR expression, and optical signal, supported by histology.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety and pharmacokinetic findings were reported?",{"text":121,"@type":113},"Plasma concentrations were measured after injection, with reported maximal levels at about 1 hour and a half-life of 12 hours. No drug-related or serious adverse events were observed under close safety monitoring.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367032,1790465965,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Ivyspring  \nInternational Publisher  \nTheranostics  \n2025; 15(1): 52-67. doi: 10.7150/thno.100042  \nResearch Paper  \nOptical molecular imaging in oral-and oropharyngeal squamous cell carcinoma using a novel uPAR-targeting near-infrared imaging agent FG001 (ICG-Glu-GluAE105): An explorative phase II clinical trial  \nAmanda Oester Andersen1,2,*, Anders Christensen1,2,*, Karina Straede2,4, Mads Lawaetz1, Christoffer Holst Hahn1, Nicklas Rubek1, Irene Wessel1, Giedrius Lelkaitis3, Katalin Kiss3, Natasja Paaske1, Anne Poulsen4, Christian von Buchwald1, Andreas Kjaer2,4􀀍  \n1. Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Denmark.  \n2. Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (CMI), Copenhagen University Hospital, Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Denmark.  \n3. Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Denmark.  \n4. FluoGuide A/S, Copenhagen, Denmark.  \n*: Shared first authors.  \n􀀍 Corresponding author: Prof. Andreas Kjaer, [akjaer@sund.ku.dk](akjaer@sund.ku.dk).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.06.24; Accepted: 2024.09.25; Published: 2025.01.01  \nAbstract  \nBackground: In oral and oropharyngeal squamous cell carcinoma (OSCC, OPSCC), frequent inadequate surgical margins highlight the importance of precise intraoperative identification and delineation of cancerous tissue for improving patient outcomes.  \nMethods: A prospective, open-label, single-center, single dose, exploratory phase II clinical trial (EudraCT 2022-001361-12) to assess the efficacy of the novel uPAR-targeting near-infrared imaging agent, FG001, for intraoperative detection of OSCC and OPSCC. Macroscopic tumor detection was quantified with sensitivity and intraoperative tumor-to-background ratio (TBR). Microscopic tumor-specificity was assessed by analysis of morphological co-localization between tumor tissue, uPAR-expression, and optical signal. Blood samples were collected up to 44 hours post-injection to further characterize the pharmacokinetic profile of the agent. The trial was conducted with close safety monitoring.  \nResults: Sixteen patients undergoing primary surgical resection were systemically administered 36 mg (n = 4), 16 mg (n = 8), or 4 mg (n = 4) of FG001 the evening prior to surgery. Intraoperatively, using a near-infrared imaging system, real-time optical imaging successfully identified all 16 tumors (sensitivity: 100%, mean TBR: 2.99 range: 2.02 – 3.95), and tumor-specificity was confirmed by histology. Clinical neck metastasis was detected with optical imaging. The maximal plasma concentrations were measured after 1 hour, and the half-life of FG001 was 12 hours. No drug-related or serious adverse events were observed.  \nConclusions: FG001 holds great potential for optical molecular imaging of OSCC and OPSCC. Further trials are warranted to explore FG001 for intraoperative margin delineation and as a decision-making tool.  \nKeywords: head and neck cancer, fluorescence-guided surgery, optical imaging, uPAR, near-infrared  \nIntroduction  \nOral and oropharyngeal squamous cell carcinoma (OSCC, OPSCC) are accountable for a significant global disease burden, with 476,100 new cases and 225,900 deaths yearly [1] . Surgical resection  \nof tumors and metastases remains a principal therapeutic modality in managing OSCC and OPSCC. The surgical procedure aims to achieve complete removal of cancerous tissue while minimizing  \nfunctional impairment, including effects on speech, swallowing, and upper airway functions [2,3] . The extent of tumor resection thereby inherently implies","cbCaisT4OiOFVTni","https://ap.wps.com/l/cbCaisT4OiOFVTni","pdf",9870308,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What clinical problem does the trial address in OSCC and OPSCC surgery?\",\"answer\":\"In oral and oropharyngeal squamous cell carcinoma, inadequate surgical margins can leave viable tumor cells, driving recurrence risk and worsening survival outcomes. The study targets the need for more precise intraoperative identification and delineation of cancerous tissue.\"},{\"question\":\"How was FG001 evaluated during the exploratory phase II trial?\",\"answer\":\"The trial assessed intraoperative real-time optical detection using sensitivity and tumor-to-background ratio (TBR). Microscopic specificity was evaluated by co-localization analysis between tumor tissue, uPAR expression, and optical signal, supported by histology.\"},{\"question\":\"What safety and pharmacokinetic findings were reported?\",\"answer\":\"Plasma concentrations were measured after injection, with reported maximal levels at about 1 hour and a half-life of 12 hours. No drug-related or serious adverse events were observed under close safety monitoring.\"}]","Optical molecular imaging in oral-and oropharyngeal squamous cell carcinoma using a novel uPAR-targeting near-infrared imaging agent FG001 - An explorative phase II clinical trial | PDF",1790168912,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecba1a2182da9be90939d618675c7736.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc040a5afb2bf4bb2d6a0eaaebdebde6.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52d879d01e558f9b08e59983be8b793d.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6f52f9ad2bdd80585152851370622e7.webp",980,1268]